Bilaketaren emaitzak - Shanu Modi

Findu emaitzak
  1. 1
    Ganetespib: research and clinical development

    Ganetespib: research and clinical development nork Shanu Modi, Komal Jhaveri

    Argitaratua 2015
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  2. 2
    HER2 breast cancer therapies: a review

    HER2 breast cancer therapies: a review nork Shanu Modi, Conleth G. Murphy

    Argitaratua 2009
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Unlocking the potential of antibody–drug conjugates for cancer therapy

    Unlocking the potential of antibody–drug conjugates for cancer therapy nork Joshua Z. Drago, Shanu Modi, Sarat Chandarlapaty

    Argitaratua 2021
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  4. 4
    Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions

    Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions nork Emanuela Ferraro, Joshua Z. Drago, Shanu Modi

    Argitaratua 2021
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers

    Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers nork Komal Jhaveri, Tony Taldone, Shanu Modi, Gabriela Chiosis

    Argitaratua 2011
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment

    Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment nork Hardik Patel, Shanu Modi, Gabriela Chiosis, Tony Taldone

    Argitaratua 2011
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  7. 7
    Beyond HER2: Targeting the ErbB receptor family in breast cancer

    Beyond HER2: Targeting the ErbB receptor family in breast cancer nork Joshua Z. Drago, Emanuela Ferraro, Nour Abuhadra, Shanu Modi

    Argitaratua 2022
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  8. 8
    Incidence of chemotherapy‐induced, long‐term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane

    Incidence of chemotherapy‐induced, long‐term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane nork Monica Fornier, Shanu Modi, Katherine S. Panageas, Larry Norton, Clifford A. Hudis

    Argitaratua 2005
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  9. 9
    Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer

    Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer nork Giuseppe Curigliano, Rebecca Dent, H. Earle, Shanu Modi, Paolo Tarantino, Giulia Viale, Sara M. Tolaney

    Argitaratua 2024
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  10. 10
    Chaperome heterogeneity and its implications for cancer study and treatment

    Chaperome heterogeneity and its implications for cancer study and treatment nork Tai Wang, Anna Rodina, Mark Dunphy, Adriana Corben, Shanu Modi, Mónica L. Guzmán, D.T. Gewirth, Gabriela Chiosis

    Argitaratua 2018
    Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  11. 11
    A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer

    A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer nork Muralidhar Beeram, Ian E. Krop, Howard A. Burris, Sandhya Girish, Wei Yu, Michael W. Lu, Scott N. Holden, Shanu Modi

    Argitaratua 2012
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  12. 12
    Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer

    Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer nork Ian E. Krop, Shanu Modi, Patricia LoRusso, Mark D. Pegram, Ellie Guardino, Betsy Althaus, Dan Lu, Alexander Strasak, Anthony Elias

    Argitaratua 2016
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  13. 13
    Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer

    Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer nork Azael Freites‐Martínez, Jerry Shapiro, Donald Chan, Monica Fornier, Shanu Modi, Devika Gajria, Stephen W. Dusza, Shari Goldfarb, Mario E. Lacouture

    Argitaratua 2018
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  14. 14
    Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

    Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies nork Paolo Tarantino, Roberto Carmagnani Pestana, Chiara Corti, Shanu Modi, Aditya Bardia, Sara M. Tolaney, Javier Cortés, Jean‐Charles Soria, Giuseppe Curigliano

    Argitaratua 2021
    Testu osoa Testu osoa
    Revisão
    Gogokoenen artean sartu
    Gorde:
  15. 15
    The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation

    The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation nork T. Jonathan Yang, Monica Morrow, Shanu Modi, Zhigang Zhang, Kate Krause, Chun Siu, Beryl McCormick, Simon N. Powell, Alice Y. Ho

    Argitaratua 2015
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  16. 16
    A Reversible Case of Advanced Interstitial Lung Disease in a Patient with HER2 Low Metastatic Breast Cancer Treated with Trastuzumab Deruxtecan

    A Reversible Case of Advanced Interstitial Lung Disease in a Patient with HER2 Low Metastatic Breast Cancer Treated with Trastuzumab Deruxtecan nork Felipe Marques da Costa, Milena Tenório Cerezoli, Augusto Kreling Medeiros, Gabriela Machado Novaes, B.R. da Silva, Fernando Cotait Maluf, Shanu Modi

    Argitaratua 2023
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  17. 17
    A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors

    A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors nork Komal Jhaveri, Kathy D. Miller, Lee S. Rosen, Bryan P. Schneider, Linnea Chap, Alison L. Hannah, Ziyang Zhong, Weining Ma, Clifford A. Hudis, Shanu Modi

    Argitaratua 2012
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  18. 18
    A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer

    A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer nork Shanu Modi, Cristina Saura, Charles Henderson, Nancy U. Lin, Reshma Mahtani, Jill Goddard, Eduard Ródenas‐Alesina, Clifford A. Hudis, Joyce O’Shaughnessy, José Baselga

    Argitaratua 2013
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  19. 19
    Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: a pooled analysis of two phase I studies

    Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2–expressing salivary gland carcinoma: a pooled analysis of two phase I studies nork Shunji Takahashi, Hideaki Bando, Ichiro Kinoshita, Shanu Modi, Junji Tsurutani, Yung‐Jue Bang, Yuta Sato, Shunsuke Nakatani, Caleb Lee, Masahiro Sugihara, Yasuyuki Okuda, Hiroji Iwata

    Argitaratua 2024
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  20. 20
    Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer

    Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer nork Sarat Chandarlapaty, Rita A. Sakr, Dilip D. Giri, Sujata Patil, Adriana Heguy, Monica Morrow, Shanu Modi, Larry Norton, Neal Rosen, Clifford A. Hudis, Tari A. King

    Argitaratua 2012
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: